Introgen Wins Decision Against Schering-Plough At European Patent Office

Law360, New York (June 3, 2005, 12:00 AM EDT) -- Introgen Therapeutics Inc. said it won a patent battle with Schering-Plough Corp. that clears the path for commercialization of its Advexin cancer treatment in Europe.

The biopharmaceutical company said it won the decision on its opposition of European Patent 0-390-323 before the European Patent Office.

Introgen said all claims directed to therapeutic applications of the p53 gene, the active component of the company's Advexin molecular therapy, were revoked by the EPO's technical board of appeals.

The patent, entitled Detection of Loss of the Wild-Type p53 Gene,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.